Completed PHASE2 INTERVENTIONAL NCT00005795

Arsenic Trioxide in Treating Patients With Acute Myeloid Leukemia

Phase II Trial of Arsenic Trioxide in Relapsed and Refractory Acute Myeloid Leukemia, Secondary Leukemia, and/or Newly-Diagnosed Patients Greater Than or Equal to 65 Years Old

Sponsor: National Cancer Institute (NCI)

Conditions Leukemia

Interventions arsenic trioxide

Updated 7 times since 2017 Last updated: Jun 7, 2012 Started: Feb 29, 2000 Primary completion: Jul 31, 2002 Completion: Jul 31, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00005795, this PHASE2 trial focuses on Leukemia and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 7 times since 2000, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Feb 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
Northwestern University

Data source: Northwestern University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chicago, United States